Company news

Noxopharm Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Promising Data Leads to Expansion of LuPIN Trial

May 22, 2019

LuPIN Trial Demonstrates High Rates of Response

May 20, 2019

DARRT Treatment Has Lasting Disease Control at Six Months

May 2, 2019

Veyonda and Immuno-Oncology Effect Explained

April 28, 2019

Idronoxil Confirmed as New Immuno-Oncology Drug

April 16, 2019

Veyonda Chemotherapy Enhancement Program to be Expanded

April 9, 2019

KZA: Kazia sells stake in Noxopharm

March 19, 2019

Noxopharm to expedite Veyonda Clinical Program

February 20, 2019

FNN interview with Nox Chief Medical Officer on Interim Data

February 6, 2019

Veyonda and Radiotherapy Delivers Clinical Benefits

February 5, 2019

Principal Investigator Discusses LuPIN-1 Study

January 13, 2019

NOX Receives $3.26M Federal Govt R&D Rebate

December 20, 2018

DARRT-1 study advancing on basis of positive clinical data

December 10, 2018

NOX announces Positive Data from CEP-1 Study of Veyonda

November 28, 2018

NOX to Present Clinical Data at COSA Annual Meeting

November 12, 2018

Appendix 4C - quarterly

October 25, 2018

Change of Registry Address: Automic P/L - Sydney Office

September 28, 2018

NOX Subsidiary Announces Important Drug Discovery

September 24, 2018

NOX to support expanded LuPIN study

September 4, 2018

Nyrada-Key progress with cholesterol-lowering drug candidate

August 26, 2018

VEYONDA - Registered Trade Mark for NOX66

August 20, 2018

Release of DARRT-1 Preliminary Safety Data

July 8, 2018

Pre-Clinical data confirms Radio-Enhancing potential

July 4, 2018

End-of-Study Clinical Data shows benefit of NOX66

June 5, 2018

NOX to present at American Society of Clinical Oncology

May 21, 2018

NOX CEO interview on near complete NOX66 chemotherapy trial

May 3, 2018

NOX CEO interview on Radiotherapy Clinical Programs

April 27, 2018

St Vincents Hospital study passes first milestone

April 16, 2018

DARRT-1 Clinical Study commences

April 5, 2018

NOX raises $10.8 M to advance clinical program

March 22, 2018

Evidence of Abscopal Responses in Patients

March 20, 2018

NOX Reports NOX66 Clinical Data

March 5, 2018

Appendix 4D and Half Year Accounts

February 22, 2018

NOX closes $4m capital raising for US subsidiary Nyrada Inc

February 15, 2018

NOX receives FY17 R&D Tax Rebate

January 17, 2018

EOY Guidance on 2018 NOX66 Clinical Development Strategy

December 21, 2017

Nyrada Inc Opens Capital Raise - Memorandum Released

November 30, 2017

NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model

November 28, 2017

Clarification of Incorrect Information

November 23, 2017

Promising Interim Clinical Data for NOX66

November 19, 2017

1st Patient treated in Lupin Study at St Vincents Hospital

November 15, 2017

UNSW collaboration confirms drug designed for stroke victims

November 2, 2017

Australian NOX66 - Radiotherapy Study Opens

September 26, 2017

Establishment of Nyrada Inc.

September 24, 2017

Positive Clinical Outcomes for NOX66 at ESMO Conference

September 11, 2017

Important Brain Cancer Findings for NOX66 Program

August 29, 2017

Reinstatement to Official Quotation

August 24, 2017

Noxopharm raises $5.5 million to advance clinical program

August 23, 2017

Suspension from Official Quotation

August 22, 2017

Noxopharm provides update on NOX66 Clinical Trial Program

July 5, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 53 decks. Every deck is listed under its year.